Taro Pharmaceutical Industries (NYSE:TARO) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Taro Pharmaceutical Industries (NYSE:TARO) in a research report report published on Saturday. The brokerage issued a strong-buy rating on the stock.

Separately, HC Wainwright downgraded Taro Pharmaceutical Industries from a buy rating to a neutral rating and set a $43.00 target price for the company. in a report on Thursday, January 18th.

Taro Pharmaceutical Industries Price Performance

TARO opened at $42.48 on Friday. Taro Pharmaceutical Industries has a one year low of $24.69 and a one year high of $45.76. The business has a 50 day simple moving average of $42.14 and a two-hundred day simple moving average of $40.11. The firm has a market capitalization of $1.60 billion, a price-to-earnings ratio of 34.82 and a beta of 0.61.

Hedge Funds Weigh In On Taro Pharmaceutical Industries

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC purchased a new stake in Taro Pharmaceutical Industries in the third quarter worth about $65,000. PenderFund Capital Management Ltd. bought a new position in shares of Taro Pharmaceutical Industries in the 4th quarter worth approximately $92,000. Strs Ohio lifted its stake in shares of Taro Pharmaceutical Industries by 58.8% in the 3rd quarter. Strs Ohio now owns 2,700 shares of the company’s stock valued at $101,000 after purchasing an additional 1,000 shares during the period. FNY Investment Advisers LLC bought a new stake in shares of Taro Pharmaceutical Industries during the fourth quarter valued at approximately $105,000. Finally, SG Americas Securities LLC purchased a new stake in Taro Pharmaceutical Industries in the third quarter worth $141,000. Hedge funds and other institutional investors own 91.40% of the company’s stock.

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products.